Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, Japan.
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Okayama, Japan.
Int J Hematol. 2021 Sep;114(3):401-407. doi: 10.1007/s12185-021-03157-z. Epub 2021 Apr 27.
Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare indolent B-cell neoplasm, and a gain-of-function mutation in the myeloid differentiation primary response 88 (MYD88), L265P, is a commonly recurring mutation in patients with WM/LPL. Histological transformation of WM/LPL to an aggressive lymphoma such as diffuse large B-cell lymphoma (DLBCL) is rare, and transformed DLBCL has a worse prognosis than de novo DLBCL, partly because transformed DLBCL is mostly classified as non-germinal center B-cell-like (non-GCB) subtype. We herein describe a 75-year-old man with DLBCL with a history of WM/LPL. DLBCL in this patient showed the GCB subtype, and the light chain restriction of DLBCL was different from that of the antecedent WM/LPL, indicating that the two types of lymphoma cells had distinctive origins. However, DLBCL in this patient harbored the MYD88 L265P mutation, and polymerase chain reaction and Sanger sequencing of the DLBCL and WM/LPL for immunoglobulin heavy chain gene rearrangement suggested a clonal relationship between the two lymphomas. Since the outcome of transformed DLBCL is worse than for de novo DLBCL, it is important to evaluate the clonal relationship between primary WM/LPL and the corresponding transformed DLBCL, even if the DLBCL expresses a GCB subtype or discordant light chain restriction.
华氏巨球蛋白血症 (WM)/淋巴浆细胞淋巴瘤 (LPL) 是一种罕见的惰性 B 细胞肿瘤,髓系分化初级反应 88 (MYD88) 的功能获得性突变,L265P,是 WM/LPL 患者中常见的反复突变。WM/LPL 向侵袭性淋巴瘤(如弥漫性大 B 细胞淋巴瘤 (DLBCL))的组织学转化较为罕见,而转化型 DLBCL 的预后比初发性 DLBCL 差,部分原因是转化型 DLBCL 大多被归类为非生发中心 B 细胞样(non-GCB)亚型。本文描述了一例有 WM/LPL 病史的 DLBCL 老年男性患者。该患者的 DLBCL 为 GCB 亚型,而 DLBCL 的轻链限制与先前的 WM/LPL 不同,表明两种淋巴瘤细胞起源不同。然而,该患者的 DLBCL 携带 MYD88 L265P 突变,对 DLBCL 和 WM/LPL 的免疫球蛋白重链基因重排进行聚合酶链反应和 Sanger 测序提示两种淋巴瘤存在克隆关系。由于转化型 DLBCL 的预后比初发性 DLBCL 差,因此评估原发性 WM/LPL 和相应转化型 DLBCL 之间的克隆关系非常重要,即使 DLBCL 表达 GCB 亚型或不相符的轻链限制。